Associations Between Metabolomics Findings and Brain Hypometabolism in Mild Cognitive Impairment and Alzheimer’S Disease# Publisher Pubmed



M Mir MOEIN ; P Khosravani PARINAZ ; E Ramezannezhad ELHAM ; Fp Saadabad Fatemeh POURALI ; M Falahati MARJAN ; M Ghanbarian MAHSA ; P Saberian PARSA ; Mr Sadeghi Mohammad REZA ; N Niknam NAFISE ; Se Ghejelou Sanaz ESKANDARI
Source: Current Alzheimer Research Published:2024

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease with rising prevalence due to the aging global population. Existing methods for diagnosing AD are struggling to detect the condition in its earliest and most treatable stages. One early indicator of AD is a substantial decrease in the brain’s glucose metabolism. Metabolomics can detect disturbances in biofluids, which may be advantageous for early detection of some AD-related changes. The study aims to predict brain hypometabolism in Alzheimer's disease using metabolomics findings and develop a predictive model based on metabolomic data. Methods: The data used in this study were acquired from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. We conducted a longitudinal study with three assessment time points to investigate the predictive power of baseline metabolomics for modeling longitudinal fluorodeoxyglucose-positron emission tomography (FDG-PET) trajectory changes in AD patients. A total of 44 participants with AD were included. The Alzheimer's Disease Assessment Scale (ADAS), the Mini-Mental State Examination (MMSE), and the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) were used for cognitive assessments. A single global brain hypo-metabolism index was used as the outcome variable. Results: Across models, we observed consistent positive relationships between specific cholesterol esters - CE (20:3) (p = 0.005) and CE (18:3) (p = 0.0039) - and FDG-PET metrics, indicating these baseline metabolites may be valuable indicators of future PET score changes. Selected triglycerides like DG-O (16:0-20:4) also showed time-specific positive associations (p = 0.017). Conclusion: This research provides new insights into the disruptions in the metabolic network linked to AD pathology. These findings could pave the way for identifying novel biomarkers and potential treatment targets for AD. #Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/ how_to_apply/ADNI_Acknowledgement_List.pdf © 2025 Elsevier B.V., All rights reserved.